|
|
Post by Hot Christian Stocks on Dec 20, 2013 7:27:47 GMT -5
$NVLX Nuvilex's Provides Progress Update on Cell Cloning Being Performed by Inno Biologics 2013-12-19 09:30 ET - News Release SILVER SPRING, Md., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, provided an update today on the progress made by its contractor, Inno Biologics, regarding the cloning of the cancer-prodrug ifosfamide-activating cells that form the basis for the cancer treatment and will be encapsulated as part of the development of the treatment for Nuvilex's future clinical trials in advanced pancreatic cancer. The cells being cloned at Inno Biologics are those that are able to convert ifosfamide, an anti-cancer prodrug, into its cancer-killing form. Ultimately, the cells obtained will be encapsulated using the Cell-in-a-Box™ cellulose-based live cell encapsulation technology. Together with ifosfamide, the encapsulated cells form Nuvilex's treatment for advanced pancreatic cancer that will be used in the Company's future clinical trials. To date, the cloning process at Inno Biologics has been going well with initial clones that have been isolated using the "State-of-the-Art" Clone-Pix™ technology that allows for optimization of the clone isolation process. The To date, the cloning process at Inno Biologics has been going well with initial clones that have been isolated using the "State-of-the-Art" Clone-Pix™ technology that allows for optimization of the clone isolation process. In addition, a strategic planning meeting was held the week of November 24, 2013 to assess issues regarding the ongoing cloning activities. Participants included Dr. Robert F. Ryan, Nuvilex's Chief Scientific Officer, Datuk Dr. Ahmed Tasir Bin Lope Pihie, CEO of Inno Biologics, Dr. Walter H. Gunzburg, Chairman and Chief Technical Officer of Austrianova and Dr. Brian Salmons, CEO and President of Austrianova from whose company the rights to use the Cell-in-a-Box™ technology for the development of cancer treatments were acquired. In commenting on the cloning process, Dr. Ryan stated, "We are confident with the results of the initial cloning process to this point which showed its capabilities to isolate multiple clones that were grown from single cells. This is critical as we move this project forward to insure the reproducibility of the future cancer treatments being advanced here at Nuvilex. We continue to make progress toward our goal of bringing this treatment option to clinical trials for advanced inoperable pancreatic cancer." www.stockwatch.com/News/Item.aspx?bid=U-z10062059-U%3aNVLX-20131219&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Dec 20, 2013 12:35:33 GMT -5
$NVLX Readies for Late-Stage Trials as NCI Seeks New Pancreatic Cancer Drugs National Cancer Institute Seeking a New Pancreatic Cancer Treatment as Death Rates Rise December 20, 2013 / There may be a more optimistic future on the horizon for those afflicted by pancreatic cancer. Currently, Eli Lilly’s (LLY) Gemzar® (gemcitabine) is the only single‐agent FDA ‐ approved (in 1996) drug to treat the disease that a November article in the Journal of the National Cancer Institute stated will become the number two cause of cancer deaths in the next decade. In September, the FDA approved Celgene’s (CELG) Abraxane®, a nanoparticle formulation of albumin with the widely used anticancer drug paclitaxel (Taxol®), in combination with gemcitabine. Major reasons for the FDA approval of the Abraxane® plus gemcitabine combination included a median survival time of 8.5 months as compared to 6.7 months for gemcitabine alone and a one‐year survival rate that was increased by 59% over that seen with gemcitabine alone. Shares of Celgene have more than doubled in 2013 to $170, in part because of the approval of the Abraxane/gemcitabine combination. What if there’s something even better than Gemzar® (gemcitabine) or Abraxane + gemcitabine? Nuvilex, Inc. (NVLX) may be bringing that caliber of a therapeutic down its pipeline with its treatment for pancreatic cancer that is composed of the well‐known anti‐cancer prodrug ifosfamide and the cellulose‐based, live‐cell encapsulation technology for a variety of hard‐to‐treat diseases, such as cancer and diabetes. As a prodrug, ifosfamide must be converted (activated) into its cancer killing form before it is effective. The cell encapsulation technology, called “Cell‐in‐a‐Box™,” is a novel platform that puts ifosfamide‐activating cells into pin‐head‐sized, spherical capsules that are then implanted into patients with advanced, inoperable pancreatic cancer, near the pancreas and therefore the tumor itself. By activating the anti‐cancer drug very near the tumor, the cancer‐killing effects of the ifosfamide are optimized. In Phase 1/2 clinical trials using the Cell‐in‐a‐Box™/ifosfamide combination treatment, when the results were compared with those from pivotal studies used by the FDA to approve Gemzar®, the Cell‐ in‐a‐Box™/ifosfamide combination gave a median survival time of 11 months as compared to 5.7 months for Gemzar® and a one‐year survival rate (36%) that was double that seen with Gemzar®. By comparison, as noted above, in the pivotal trial that led to the approval of Celgene’s Abraxane®/gemcitabine combination, patients treated with that combination had a one‐year survival rate that was 59% greater than that for gemcitabine and a median survival time of 8.5 months versus 6.7 months with gemcitabine alone. If the above apparent superiority of the Cell‐in‐a‐Box™/ifosfamide combination as compared to either Gemzar® or the Abraxane®/gemcitabine combination sounds amazing, that’s because it is, particularly if one realizes that, since 1996, only two treatments have been approved by the FDA for the treatment of advanced, inoperable pancreatic cancer with the latest and best being Celgene’s Abraxane®/gemcitabine combination. But it even gets better. Whereas serious side effects were seen in patients receiving treatment with Gemzar® or the Abraxane®/gemcitabine combination, no serious side effects were seen in patients treated with the Cell‐in‐a‐Box™/ifosfamide combination. This is because, patients in the Phase 1/2 trials with the latter combination were given ifosfamide at only one‐third of the dose normally administered when this anti‐cancer drug is used alone to treat cancers, whereas patients in the pivotal trials for Gemzar® or the Abraxane®/gemcitabine combination were given the highest doses that they could tolerate. The reduced side effect profile seen with the Cell‐in‐a‐Box™/ifosfamide treatment resulted in an overall better “quality‐of‐life” for the patients. Nuvilex is in the midst of preparing for late‐stage trials to evaluate the Cell‐in‐a‐Box™/ifosfamide combination directly against gemcitabine, similar to what Celgene just did. If the results replicate the Phase 1/2 data and outperform not only gemcitabine, but also the Abraxane®/gemcitabine combination, whil e at the same time reducing the side effects associated with the treatment of advanced, inoperable pancreatic cancer, the days of Nuvilex trading at 12 cents per share will be a distant memory. Savvy biotech investors know that the time to invest is before clinical data arrives in order to catch the full breadth of a move, particularly if positive top‐line results are delivered, meaning that now, not later, is the time to be taking a close look at Nuvilex, Inc. (NVLX) and its acquisition of the rights to use a unique live‐cell encapsulation technology that could revolutionize treatments for pancreatic cancer as well as other deadly diseases. About Baystreet Media Group (BMG): BMG is a full service Investment Relations firm. For more information and to read disclaimers and disclosures: www.baystreetmediagroup.comfinance.yahoo.com/news/nuvilex-readies-stage-trials-nci-160500382.html |
|
|
|
Post by Hot Christian Stocks on Jan 12, 2014 22:54:10 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 13, 2014 9:47:03 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 14, 2014 8:10:45 GMT -5
$NVLX – Must listen to interview by Dr. Gerald Crabtree Discussing Nuvilex Phase 3 Trials, Study Sites, Technology & More ow.ly/qkcH4 |
|
|
|
Post by Hot Christian Stocks on Jan 14, 2014 8:11:05 GMT -5
$NVLX – Must listen to interview by Dr. Gerald Crabtree Discussing Nuvilex Phase 3 Trials, Study Sites, Technology & More ow.ly/qkcH4 |
|
|
|
Post by Hot Christian Stocks on Jan 14, 2014 9:38:52 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 15, 2014 9:54:12 GMT -5
$NVLX Nuvilex is currently into its preparations for late-phase clinical trials in advanced, inoperable pancreatic cancer using Cell-in-a-Box, and these trials will only add to the experience the company's executives will have using this technology. Given the solid team they're putting together at MMS, they will likely use that experience to enhance the medical marijuana industry's search for cures to many types of cancer. www.stockwatch.com/News/Item.aspx?bid=U-i1081571-U%3aNVLX-20140114&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Jan 16, 2014 9:06:20 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 17, 2014 9:37:16 GMT -5
$NVLX – Check out this interview of Nuvilex Upcoming Phase 3 Trials, Study Sites, Study Protocol & More ow.ly/qkcH4 |
|
|
|
Post by Hot Christian Stocks on Jan 21, 2014 8:59:35 GMT -5
Nuvilex, Inc. (OTCQB: NVLX) and a host of marijuana companies are keeping a close eye on what is happening with a petition drive in Florida to get the use of medical marijuana on ballots in time for the November election. Why is Florida important? Well, for a company like Nuvilex and its medical marijuana subsidiary, Marijuana Sciences, Inc., conducting research and developing treatments using the drug are made far easier if the country moves to full acceptance, and Florida could be the domino that sets the last of the states holding out in motion.
|
|
|
|
Post by Hot Christian Stocks on Jan 21, 2014 9:43:13 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 22, 2014 9:54:02 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 22, 2014 10:52:34 GMT -5
$NVLX targeted by Catalysts in the marijuana and medical marijuana industry Baltimore, Maryland - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, recently published a new research update on Nuvilex Inc. (OTCQB – NVLX). In the update, senior analyst Rob Goldman outlines his latest thesis. "A series of recent landmark events in the marijuana and medical marijuana space, along with a revaluation of biotechs, are set to serve as triggers prompting the accumulation and rise of Nuvilex’s stock back to the levels enjoyed roughly 9 months ago." Nuvilex is a biotechnology company with the rights to a novel cellulose-based live-cell encapsulation technology, called Cell-in-a-BoxTM, that will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon the well-known chemical constituents of marijuana. Nuvilex is exploring ways in which the Cell-in-a-BoxTM technology may play a role in these efforts. According to Goldman, the aforementioned triggers include a surge of interest in, and validation of, medical marijuana and the publicly traded firms that operate in the space. Catalysts cited in the research update include a tacit marijuana endorsement by President Obama, which could give a huge shot in the arm to the sector. Plus, given that Colorado’s tax revenue-generating pot shops cannot keep product on the shelves, cash-strapped states and municipalities may view a softening stance on this topic as a tangible opportunity to generate real revenue. In addition, the swift and broad shift in support toward medical marijuana will likely be enhanced during the 2- week Super Bowl marketing period. Since the two participants hail from the states that have legalized marijuana, it is likely that proponents will flood the media with stories on the topic, placing it near the top of the talking points food chain. Finally, Goldman notes that major moves have occurred of late in other anti-cancer stocks while biotech investors seek to find the next biotech slated to move in concert with the launch of upcoming events. With a series of milestone events ahead for the Company, investors could enjoy similar moves as these milestones are achieved, as evidenced by the achievements of its peer group and the subsequent rises in their stock prices. ih.advfn.com/p.php?pid=nmona&article=60756169 |
|
|
|
Post by Hot Christian Stocks on Jan 23, 2014 8:38:51 GMT -5
$NVLX WEALTHMAKERS.COM projected fundamental full valuation of $1.90 per share SILVER SPRING, Md., Jan. 23, 2014 (GLOBE NEWSWIRE) -- WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Nuvilex, Inc. (OTC:NVLX). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price and the projected fundamental full valuation of $1.90 per share www.stockwatch.com/News/Item.aspx?bid=U-z10065185-U%3aNVLX-20140123&symbol=NVLX®ion=U |
|
